Stay informed on the latest Truth Social posts from Donald Trump (@realDonaldTrump) without the doomscrolling. Consider it a public service for your mental health. (Why?)
Filtering by entity: AbbVie | Clear Filter
Summary:A letter from The White House, signed by Donald J. Trump and dated July 31, 2025, addresses AbbVie and other drug manufacturers, stating an Executive Order from May 12, 2025, aims to implement Most-Favored-Nation (MFN) drug pricing for American patients, demanding that US drug prices match those in other developed nations. The letter outlines specific demands for drug manufacturers, including extending MFN pricing to Medicaid, guaranteeing it for newly-launched drugs, repatriating foreign revenues, and participating in direct purchasing models, with a deadline for compliance by September 29, 2025, and a warning of further action if compliance is not met.
Sentiment:Directive
Key Claims:
- An Executive Order was signed on May 12, 2025, to deliver Most-Favored-Nation (MFN) prescription drug pricing to American patients.
- American brand name drug prices are up to three times higher than elsewhere, a result of 'global freeloading'.
- The Administration rejects policy changes that would result in 'billions of dollars in handouts to industry'.
- AbbVie and other drug manufacturers are called to extend MFN pricing to Medicaid for existing drugs.
- Drug manufacturers must guarantee MFN pricing for newly-launched drugs to Medicare, Medicaid, and commercial payers.
- Increased revenues generated abroad must be repatriated to lower drug prices for American patients and taxpayers.
- Drug manufacturers should provide for Direct Purchasing at MFN pricing via Direct-to-Consumer (DTC) and/or Direct-to-Business (DTB) models.
- The Administration will 'deploy every tool in our arsenal' if drug manufacturers do not comply with the demands.
- Binding commitments to meet these goals are expected by September 29, 2025.
Potential Market Impact (S&P 500):8/10
Potential Geopolitical Risk:0/10
Potential Global Cross-Asset Impact:7/10
« Previous
Page 1 of 1
Next »